FDA Approves Pertuzumab for Advanced, Her2+ Breast Cancer
My opinion is not quite formed on this new antibody. The FDA’s decision was based on results of one trial of 808 patients, half of whom didn’t get the experimental drug…
FDA Approves New Assay for Her2 in Breast Cancer
This week the FDA approved a new assay for Her2 expression in breast cancer biopsies. The technology, Inform Dual ISH, is manufactured by Ventana Medical Systems, a Roche subsidiary. Inform Dual ISH works like this: technicians, typically working under the supervision of a pathologist, expose a tiny bit of a breast biopsy specimen, fixed on […]